Abstract

Coronavirus Disease (COVID-19) is an infectious disease caused by the SARS-CoV-2 virus, which is a contagious respiratory virus causing atypical pneumonia COVID-19 in adult and children with Severe Acute Respiratory Syndrome (SARS). The SARS-CoV-2 genome also encodes four structural (S, E, M and N) and up to six accessory (3a, 6, 7a, 7b, 8, and 9b) proteins. The spike protein (S) is further divided into 2 subunits, S1 and S2 that mediate host cell attachment and invasion. Anti-SARS-CoV-2 Monoclonal Antibodies (mAbs) that target the spike protein have been shown to yield clinical benefits in treating SARS-CoV-2 infection. This article represents a clinical case of a 59-year-old man with Coronavirus Disease (COVID-19) and intracerebral haemorrhage, who was treated with the use of monoclonal antibodies bamlanivimab and etesevimab. Equally, it presents a review of these drugs’ application for COVID-19 treatment in adults and children.

Keywords: Coronavirus disease (COVID-19); Monoclonal Antibodies; Bamlanivimab; Etesevimab

Abbreviations: COVID-19: Coronavirus Disease 2019; mAbs: Monoclonal Antibodies; SARS: Severe Acute Respiratory Syndrome; FDA: US Food and Drug Administration; EUA: Emergency Use Authorization; RNA: Ribonucleic Acid; NIHSS: National Institutes of Health Stroke Scale; PCR: Polymerase Chain Reaction; CRP: C-Reactive Protein; CT: Computer Tomography; ESR: Erythrocyte Sedimentation Rate